# C&D Emerging Investment

> C&D Emerging Investment is a VC fund backing Health Care, Medical and Medical Device. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 13
- Last investment: Apr 2024
- Lead investor: 8%
- Last updated: Aug 2026

C&D Emerging Investment is a VC fund focused on Health Care and Medical. C&D Emerging Investment specializing in minority equity investment.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 46% |
| Medical | 5 | 38% |
| Medical Device | 4 | 31% |
| Biotechnology | 3 | 23% |
| Pharmaceutical | 3 | 23% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 23% |
| Series C | 3 | 23% |
| Series D | 2 | 15% |
| Venture - Series Unknown | 2 | 15% |
| Series E | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| IMPACT Therapeutics | IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more thanfour decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology. | $55.3M | Series D | Apr 19, 2024 |  |
| Bang Er Orthopedic | Zhejiang Boner Medical Investment Management Co., Ltd. is a well-known professional hospital investment operator in the Yangtze River Delta, featuring major orthopaedics and rehabilitation. | $109.8M | Series E | Nov 09, 2023 |  |
| AccuPath | AccuPath is a high-tech group dedicated to enhancing human life and health via the use of modern materials & manufacturing science and technology. |  | Venture - Series Unknown | Oct 25, 2023 |  |
| Oricell Therapeutics | OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. | $45M | Series B | Feb 28, 2023 |  |
| Nuclei System Technology | A notable feature of the RISC-V architecture is its open scalability to facilitate the special needs of specialized areas. It is embodied in the instruction code space and the predefined Custom command, which is convenient for specific functions such as security or intelligent acceleration under the unified development model to make the productmore competitive. Nuclei System Technology provides customers with RISC-V related training services with the most professional technology, instruction set expansion and acceleration module design services based on core RISC-V processor IP, and dedicated high performance and low power processor design services. |  | Venture - Series Unknown | Aug 18, 2022 |  |
| OriginCell | OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments.OriginCell wasfounded in 2014 and is headquartered in Shanghai, China. | $120M | Series B | Aug 01, 2022 |  |
| Oricell Therapeutics | OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. | $120M | Series B | Aug 01, 2022 |  |
| TBSTest Technology | Yuexin Technology is a semiconductor test equipment developer specializing in R&D, production and sales of ultra-large-scale integrated circuit test equipment (ATE). Its main product is SOC test equipment, which is mainly for enterprise users of integrated circuit design, production, packaging and testing. Integrated circuit test equipment andsolutions. | $74.7M | Series C | Jun 24, 2022 |  |
| IMPACT Therapeutics | IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more thanfour decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology. |  | Series D | Mar 14, 2022 |  |
| SiBionics | SiBionics is a medtech specialized in R&D & commercialization of implantable medical devices and medical imaging artificial intelligence. | $126M | Series C | Jan 21, 2022 |  |

10 of 13 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 5 deals together
- [Legend Capital](https://shizune.co/investors/profile/legend-capital) — VC Fund, 3 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 2 deals together
- [Quan Capital](https://shizune.co/investors/profile/quan-capital) — VC Fund, 2 deals together
- [ShenZhen GTJA Investment Group](https://shizune.co/investors/profile/shenzhen-gtja-investment-group) — VC Fund, 2 deals together
- Accurate Capital — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does C&D Emerging Investment invest in?

C&D Emerging Investment invests primarily in Health Care, Medical and Medical Device startups, most often at Series B and Series C stage. Most of the 13 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did C&D Emerging Investment last invest?

The most recent investment recorded for C&D Emerging Investment closed in Apr 2024. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co